FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a pioneering biopharmaceutical company committed to developing a diverse portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, has recently announced the retention of Christian Attar Law. This regional litigation firm, based in Houston, Texas, will co-lead an investigation into potential naked short selling or other market manipulation of FSD Pharma’s common shares, alongside Alan M. Pollack of the New York City law firm Warshaw Burstein, LLP.
The company and its legal team are dedicated to gathering all evidence and records of activity to present to the appropriate authorities, such as the Department of Justice, Securities and Exchange Commission, and Ontario Securities Commission.
FSD Pharma Inc. is a biotechnology company with two candidates in different stages of development. Lucid Psychss Inc., a wholly owned subsidiary, is focused on the research and development of its lead compounds, Lucid-MS and UNBUZZD™. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD™ is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle.
